MOUNTAIN VIEW, CA — (Marketwired) — 06/18/15 — Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it will exhibit its Magellan Robotic System at the Global Embolization Symposium and Technologies (GEST) Scientific Meeting June 24 – June 27 at the FIBES II – New Conference Centre in Seville, Spain. The Company will showcase the Magellan 6Fr Robotic Catheter being used by Interventional Radiologists in embolization procedures, and will conduct Magellan Robotic System demonstrations at exhibit booth #5.
During this year–s GEST meeting, the Magellan Robotic System will be featured in a scientific session entitled “Cutting Edge Technology” and in a company sponsored symposium.
The following session during GEST will include discussion about intravascular robotics:
June 26, Parallel session: Cutting edge technology, 2:15-3:45pm, Main Auditorium
Robotic-assisted embolisation – Marc Sapoval, MD, PhD (Hopital Europeen Geoges-Pompidou)
Hansen Medical is also sponsoring an educational symposium on Wednesday, June 24 from 6:00 – 6:30 pm called “Clinical Update on Robotic Embolisation.” Two speakers, Marc Sapoval, MD, PhD (Paris, France) and Mohamad Hamady, MD (London, UK), will discuss the role of robotic technology in providing enhanced precision, control and radiation protection in endovascular procedures. This session will take place in the FIBES II – New Conference Centre, Bruselas Lecture Room.
“The GEST meeting attracts medical experts from all over the world to discuss and debate the latest advances in embolization therapies,” said Cary Vance, Hansen Medical–s President and Chief Executive Officer. “We are excited that Magellan will be discussed as a cutting edge technology. Embolization procedures offer a minimally invasive approach in areas including Women–s Health, Men–s Health, and Cancer treatment. Magellan enables patients to benefit from robotic precision and control in these procedures, while helping to protect physicians from the harmful effects of exposure to ionizing radiation.”
Hansen Medical–s Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic System offers several important features including:
Provides predictability, control and catheter stability as a physician navigates a patient–s peripheral vasculature and then provides a conduit for manual treatment of vascular disease with standard therapeutic devices.
Is designed to enable more predictable procedure times and increased case throughput potentially allowing hospitals to improve utilization within their vascular business line.
Employs an open architecture designed to allow for the subsequent use of many therapeutic devices on the market today.
Is designed to potentially reduce physician radiation exposure and fatigue by allowing the physician to navigate procedures while seated comfortably at a remote workstation away from the radiation field and without wearing heavy lead as required in conventional endovascular procedures.
The Magellan 9Fr and 10Fr Robotic Catheters allow for independent, robotic control of two telescoping catheters (an outer Guide and an inner Leader catheter), as well as robotic manipulation of standard guide wires.
The Magellan 6Fr Robotic Catheter allows for independent robotic control of two separate bend sites on a single catheter, as well as robotic manipulation of standard guide wires. This smaller catheter design may be preferred by certain physicians who prefer a smaller diameter vessel access site, or in procedures in smaller vessels.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company–s Magellan Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company–s mission is to enable cardiac arrhythmia and endovascular procedures and to improve patient outcomes through the use of intravascular robotics. Additional information can be found at .
“Hansen Medical,” “Hansen Medical (with Heart Design),” and “Heart Design (Logo)” are registered trademarks, and “Magellan” and “Hansen Medical Magellan” are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “potential,” “believes,” “goal,” “estimate,” “anticipates,” and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
You must be logged in to post a comment Login